Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials

GY Ku, BA Haaland, G de Lima Lopes Jr - Lung Cancer, 2011 - Elsevier
BACKGROUND: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
被引用次数：100 相关文章

[引用][C] Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY Ku, BA Haaland, G de Lima Lopes - Lung Cancer, 2011 - cir.nii.ac.jp
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis
of phase III trials | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY Ku, BA Haaland, G de Lima Lopes - Lung Cancer, 2011 - lungcancerjournal.info
Background Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth factor
receptor (EGFR). It has been shown to be active in patients with advanced non-small cell …

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY Ku, BA Haaland, G de Lima Lopes - Lung Cancer, 2011 - infona.pl
Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth factor receptor
(EGFR). It has been shown to be active in patients with advanced non-small cell lung cancer …

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY Ku, BA Haaland, G de Lima Lopes - 2011 - scholarbank.nus.edu.sg
Background: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth factor
receptor (EGFR). It has been shown to be active in patients with advanced non-small cell …
[PDF] academia.edu

[PDF][PDF] Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY Kua, BA Haalandc, G de Lima Lopes Jr - Lung Cancer, 2011 - academia.edu
abstract Background: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal
growth factor receptor (EGFR). It has been shown to be active in patients with advanced non …

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY Ku, BA Haaland… - Lung cancer …, 2011 - scholarship.miami.edu
Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth factor receptor
(EGFR). It has been shown to be active in patients with advanced non-small cell lung cancer …

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY Ku, BA Haaland, G de Lima Lopes - Lung Cancer, 2011 - pure.johnshopkins.edu
Background: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth factor
receptor (EGFR). It has been shown to be active in patients with advanced non-small cell …

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials

GY Ku, BA Haaland… - Lung cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth factor
receptor (EGFR). It has been shown to be active in patients with advanced non-small cell …

[引用][C] Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

GY KU, BA HAALAND, G DE LIMA LOPES - Lung cancer, 2011 - pascal-francis.inist.fr
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis
of phase III trials CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …